Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice

Neurobiology of Disease

Volumn 66, Issue , 2014, Pages 74-82

  Li, Lan ^a   Xiong, Zhi yong ^a   Qian, Zhong Ming ^a   Zhao, Tian zhi ^a   Feng, Hua ^a   Hu, Sengli ^a   Hu, Rong ^a   Ke, Ya ^b   Lin, Jiangkai ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Prince of Wales Hospital   (Hong Kong)

Author keywords

BALB c C5aR mice (C5aR ); Basso mouse scale (BMS); Complement C5a receptor antagonist (C5aRA); Microglia macrophage; Spinal cord injury (SCI)

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LOCOMOTION; MACROPHAGE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SPINAL CORD INJURY; WESTERN BLOTTING;

BALB/C C5AR MICE (C5AR-/-); BASSO MOUSE SCALE (BMS); COMPLEMENT C5A RECEPTOR ANTAGONIST (C5ARA); MICROGLIA/MACROPHAGE; SPINAL CORD INJURY (SCI);

ANIMALS; CENTRAL NERVOUS SYSTEM AGENTS; FEMALE; INTERLEUKIN-1BETA; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROGLIA; MOTOR ACTIVITY; NERVE TISSUE PROTEINS; PEPTIDES, CYCLIC; RECEPTOR, ANAPHYLATOXIN C5A; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SPINAL CORD; SPINAL CORD INJURIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84896951302     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.02.008     Document Type: Article

References (43)

1. Amar A.P., Levy M.L. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 1999, 44(5):1027-1039.
2. Anderson A.J., Robert S., Huang W., Young W., Cotman C.W. Activation of complement pathways after contusion-induced spinal cord injury. J. Neurotrauma 2004, 21:1831-1846.
3. Anderson A.J., Najbauer J., Huang W., Young W., Robert S. Upregulation of complement inhibitors in association with vulnerable cells following contusion-induced spinal cord injury. J. Neurotrauma 2005, 22(3):382-397.
4. Basso D.M., Fisher L.C., Anderson A.J., Jakeman L.B., McTigue D.M., Popovich P.G. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J. Neurotrauma 2006, 23(5):635-659.
5. Bauchet L., Lonjon N., Perrin F.E., Gilbert C., Privat A., Fattal C. Strategies for spinal cord repair after injury: a review of the literature and information. Ann. Phys. Rehabil. Med. 2009, 52:230-251.
6. Beck K.D., Nguyen H.X., Galvan M.D., Salazar D.L., Woodruff T.M., Anderson A.J. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 2010, 133(Pt 2):433-447.
7. Bracken M.B., Collins W.F., Freeman D.F., Shepard M.J., Wagner F.W., Silten R.M., Hellenbrand K.G., Ransohoff J., Hunt W.E., Perot P.L., Grossman R.G., Green B.A., Eisenberg H.M., Rifkinson N., Goodman J.H., Meagher J.N., Fischer B., Clifton G.L., Flamm E.S., Rawe S.E. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984, 251:45-52.
8. Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Young W., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J., Marshall L.F., Perot P.L., Piepmeier J., Sonntag V.K.H., Wagner F.C., Wilberger J.E., Winn H.R. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. N. Engl. J. Med. 1990, 322:1405-1411.
9. Bracken M.B., Shepard M.J., Holford T.R., Leo-Summers L., Aldrich E.F., Fazl M., Fehlings M., Herr D.L., Hitchon P.W., Marshall L.F., Nockels R.P., Pascale V., Perot P.L., Piepmeier J., Sonntag V.K.H., Wagner F., Wilberger J.E., Winn H.R., Young W. Administration of methylprednisolone for 24 or 48hours or tirilazad mesylate for 48hours in the treatment of acute spinal cord injury. JAMA 1997, 277:1597-1604.
10. Chang Y.Z., Qian Z.M., Wang K., Zhu L., Yang X.D., Du J.R., Jiang L., Ho K.P., Wang Q., Ke Y. Effects of development and iron status on ceruloplasmin expression in rat brain. J. Cell. Physiol. 2005, 204(2):623-631.
11. Chang Y.Z., Ke Y., Du J.R., Halpern G.M., Ho K.P., Zhu L., Gu X.S., Xu Y.J., Wang Q., Li L.Z., Wang C.Y., Qian Z.M. Increased divalent metal transporter 1 expression might be associated with the neurotoxicity of l-DOPA. Mol. Pharmacol. 2006, 69(3):968-974.
12. Donnelly D.J., Popovich P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp. Neurol. 2008, 209(2):378-388.
13. Du F., Qian Z.M., Zhu L., Wu X.M., Yung W.H., Tsim T.Y., Ke Y. l-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression. PLoS ONE 2009, 4(2):e4593.
14. Du F., Qian Z.M., Zhu L., Wu X.M., Chan R., Ke Y. Purity, cell viability, expression of GFAP and bystin in astrocytes cultured by different procedures. J. Cell. Biochem. 2010, 109(1):30-37.
15. Du F., Qian C., Qian Z.M., Wu X.M., Xie H., Yung W.H., Ke Y. Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP-protein kinase A pathway. Glia 2011, 59(6):936-945.
16. Galvan M.D., Luchetti S., Burgos A.M., Nguyen H.X., Hooshmand M.J., Hamers F.P., Anderson A.J. Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury. J. Neurosci. 2008, 28(51):13876-13888.
17. Gasque P., Dean Y.D., McGreal E.P., VanBeek J., Morgan B.P. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000, 49(1-2):171-186.
18. Guo Q., Li S., Liang Y., Zhang Y., Zhang J., Wen C., Lin S., Wang H., Su B. Effects of C3 deficiency on inflammation and regeneration following spinal cord injury in mice. Neurosci. Lett. 2010, 485(1):32-36.
19. Guo Q., Cheng J., Zhang J., Su B., Bian C., Lin S., Zhong C. Delayed post-injury administration of C5a improves regeneration and functional recovery after spinal cord injury in mice. Clin. Exp. Immunol. 2013, 174(2):318-325.
20. Hall E.D., Braughler J.M. Acute effects of intravenous glucocorticoid pretreatment on the in vitro peroxidation of cat spinal cord tissue. Exp. Neurol. 1981, 73:321-324.
21. +)-ATPase activity. J. Neurosurg. 1982, 57:247-253.
22. Hanigan W.C., Anderson R.J. Commentary on NASCIS-2. J. Spinal Disord. 1992, 5:125-131.
23. Hurlbert R.J., Hamilton M.G. Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Can. J. Neurol. Sci. 2008, 35:41-45.
24. Kadota R., Koda M., Kawabe J., Hashimoto M., Nishio Y., Mannoji C., Miyashita T., Furuya T., Okawa A., Takahashi K., Yamazaki M. Granulocyte colony-stimulating factor (G-CSF) protects oligodendrocyte and promotes hindlimb functional recovery after spinal cord injury in rats. PLoS One 2012, 7(11):e50391. 10.1371/journal.pone.005039.
25. Ke Y., Chen Y.Y., Chang Y.Z., Duan X.L., Ho K.P., Jiang D.H., Wang K., Qian Z.M. Post-transcriptional expression of DMT1 in the heart of rat. J. Cell. Physiol. 2003, 196(1):124-130.
26. Ke Y., Chang Y.Z., Duan X.L., Du J.R., Zhu L., Wang K., Yang X.D., Ho K.P., Qian Z.M. Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol. Aging 2005, 26(5):739-748.
27. Kwon B.K., Tetzlaff W., Grauer J.N., Beiner J., Vaccaro A.R. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J. 2004, 4:451-464.
28. Li L.M., Li J.B., Zhu Y., Fan G.Y. Soluble complement receptor type 1 inhibits complement system activation and improves motor function in acute spinal cord injury. Spinal Cord 2010, 48:105-111.
29. Plemel J.R., Duncan G., Chen K.W., Shannon C., Park S., Sparling J.S., Tetzlaff W. A graded forceps crush spinal cord injury model in mice. J. Neurotrauma 2008, 25(4):350-370.
30. Qiao F., Atkinson C., Song H., Pannu R., Singh I., Tomlinson S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am. J. Pathol. 2006, 169(3):1039-1047.
31. Qiao F., Atkinson C., Kindy M.S., Shunmugavel A., Morgan B.P., Song H., Tomlinson S. The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am. J. Pathol. 2010, 177(6):3061-3070.
32. Ray S.K., Samantaray S., Smith J.A., Matzelle D.D., Das A., Banik N.L. Inhibition of cysteine proteases in acute and chronic spinal cord injury. Neurotherapeutics 2011, 8(2):180-186.
33. Rebhuhn J., Botvin J. Complement elevation in spinal cord injury. Ann. Allergy 1980, 44:287-288.
34. Rebhun J., Madorsky J.G., Glovsky M.M. Proteins of the complement system and acute phase reactants in sera of patients with spinal cord injury. Ann. Allergy 1991, 66:335-338.
35. Sarma J.V., Ward P.A. The complement system. Cell Tissue Res. 2011, 343(1):227-235.
36. Sarma J.V., Ward P.A. New developments in C5a receptor signaling. Cell Health Cytoskeleton 2012, 4:73-82.
37. Short D. Use of steroids for acute spinal cord injury must be reassessed. BMJ 2000, 321:1224.
38. Silva N.A., Sousa N., Reis R.L., Salgado A.J. From basics to clinical: a comprehensive review on spinal cord injury. Prog. Neurobiol 2013, (Nov 20. pii: S0301-0082(13)00119-6. [Epub ahead of print]). 10.1016/j.pneurobio.2013.11.002.
39. Tator C.H. Biology of neurological recovery and functional restoration after spinal cord injury. Neurosurgery 1998, 42:696-707.
40. Woodruff T.M., Ager R.R., Tenner A.J., Noakes P.G., Taylor S.M. The role of the complement system and the activation fragment C5a in the central nervous system. Neuromol. Med. 2010, 12(2):179-192.
41. Wu J., Stoica B.A., Faden A.I. Cell cycle activation and spinal cord injury. Neurotherapeutics 2011, 8(2):221-228.
42. Wu X.M., Qian Z.M., Zhu L., Du F., Yung W., Ke Y. Neuroprotective effect of ligustilide against ischemia-reperfusion injury via up-regulation of erythropoietin and down-regulation of RTP801. Br. J. Pharmacol. 2011, 164:332-343.
43. Zhao L., Qian Z.M., Zhang C., Wing H.Y., Du F., Ya K. Amyloid beta-peptide 31-35-induced neuronal apoptosis is mediated by caspase-dependent pathways via cAMP-dependent protein kinase A activation. Aging Cell 2008, 7(1):47-57.